Venous Thrombosis (Hypercoagulability) Evaluation for Patients on VKA (Vitamin K Antagonist) Therapy

CPT: 81240; 83090; 85230; 85240; 85300; 85302; 85305; 85307; 85598; 85613(x2); 85730; 85732(x2); 86146(x3); 86147(x2) Note: Will reflex to Factor V Leiden if APCR is abnormal. If prolonged, aPTT will reflex to Immediate aPTT Mixing Studies. If the dRVVT screen is normal, the confirmation and ratio will not be performed. If reflex testing is performed, additional charges/CPT code(s) may apply.

Test Includes

aPTT, Immediate aPTT Mixing Studies, Activated Protein C Resistance, Factor V Leiden Mutation, Anticardiolipin Antibody (IgG, IgM), Antithrombin Activity, Factor II Gene Mutation (Prothrombin G20210A), dRVVT, Hexagonal Phospholipid Neutralization, Homocysteine, Protein C Antigen, Protein S Antigen Total, Factor VII Antigen, Factor VIII Activity, Protein C Antigen/Factor VII Antigen Ratio, Protein S Antigen/Factor VII Antigen Ratio, Beta-2 Glycoprotein I IgG, IgM, IgA, Lupus Anticoagulant Interpretation


Special Instructions

Informed consent required for NY patients. Will reflex to Factor V Leiden if APCR is abnormal. If prolonged, aPTT will reflex to Immediate aPTT Mixing Studies. If the dRVVT screen is normal, the confirmation and ratio will not be performed. If reflex testing is performed, additional charges/CPT code(s) may apply.


Expected Turnaround Time

3 - 7 days


Specimen Requirements


Specimen

Citrated plasma, whole blood, and serum


Volume

Three tubes, 1 mL each, citrated plasma, 5 mL whole blood, and 1 mL serum


Minimum Volume

Two tubes, 1 mL each, citrated plasma, 1.5 mL whole blood, and 1 mL serum (Note: This volume does not allow for repeat testing.)


Container

Citrated plasma: Light blue-top (sodium citrate) tube Whole blood: Lavender-top (EDTA) tube, yellow-top (ACD) tube, or light blue top (sodium citrate) tube Serum: Red-top tube


Storage Instructions

Ship plasma and serum frozen on dry ice. Ship whole blood ambient; avoid extreme temperatures.


Test Details


Limitations

This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.


Methodology

Chromogenic, clot, ELISA, FPIA, PCR